Clinical Trials Logo

Clinical Trial Summary

The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.


Clinical Trial Description

The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis, etc.). The present version (third generation) of the H3 TAR and the earlier generations of this total ankle system have been marketed (initially in 2003) under a license agreement in Europe, South Korea, Australia, and Canada and other countries outside the U.S. (OUS). The H3 TAR prosthesis has been used in over 20,000 procedures in the markets OUS. The H3 TAR device has not been withdrawn from marketing for any reason. The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04770870
Study type Interventional
Source DT MedTech, LLC
Contact Clinical Research Associate
Phone 3478223603
Email amckibbin@msquaredassociates.com
Status Recruiting
Phase N/A
Start date February 1, 2022
Completion date April 2029

See also
  Status Clinical Trial Phase
Recruiting NCT03711773 - Outcomes of Low-Impact Exercise Program for People With Ankle, Knee, and/or Hip Pain N/A
Completed NCT05275244 - Evaluate Clinical Benefit of Local Treatment With KD Intra-Articular® Gel in Patients With Osteoarthritis (NO-DOLOR2)
Recruiting NCT05912153 - SPECT-CT vs MRI for the Diagnosis of Osteoarthritis in the Foot and Ankle
Completed NCT04562896 - Iterative Design of Custom Dynamic Orthoses to Reduce Articular Contact Stress N/A
Withdrawn NCT05209347 - Custom Dynamic Orthoses to Reduce Articular Contact Stress N/A
Completed NCT04204278 - MONOVISC for Ankle Joint Pain Relief N/A